Karyopharm Therapeutics (NASDAQ:KPTI) Earns "Outperform" Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI - Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $3.00 price objective on the stock.

Several other brokerages have also weighed in on KPTI. HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, January 15th. StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, Piper Sandler raised their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.00.

Karyopharm Therapeutics Trading Up 2.8 %

NASDAQ KPTI traded up $0.02 on Monday, hitting $0.60. 605,792 shares of the company were exchanged, compared to its average volume of 789,462. Karyopharm Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.70. The firm has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.77. The company has a market cap of $75.97 million, a P/E ratio of -0.53 and a beta of 0.06.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC increased its position in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after acquiring an additional 56,613 shares during the last quarter. FMR LLC grew its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company's stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after purchasing an additional 622,194 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Karyopharm Therapeutics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company's stock worth $942,000 after purchasing an additional 36,922 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in shares of Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after buying an additional 792,283 shares during the last quarter. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).